Effect of Ginkgo biloba extract on serological indexes of diabetic rats

Chinese Journal of Biologicals

Volumn 22, Issue 2, 2009, Pages 171-173

  Yang, Shu Juan ^a   Ren, Shu Ping ^a   Chen, Qiang ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Diabetes; Extract; Ginkgo biloba; Lipid metabolism

Indexed keywords

C PEPTIDE; GINKGO BILOBA EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STREPTOZOCIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; INSULIN BLOOD LEVEL; LIPID METABOLISM; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SEROLOGY; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL;

GINKGO BILOBA; RATTUS;

EID: 77950805410     PISSN: 10045503     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Fonseca VA. The metabolic syndrome, hyperlipiddemia, and insulin resistance. Clin Cornerstone, 2005, 7(3): 61-72.
2. Chinese source.
3. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol, 2003, 91(3 Suppl 1): 3A-6A.
4. Grundy SM, Brewer HB, Cleeman JL, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation, 2004, 109(3): 433-438.
5. Welch V, Tang SS. Treatment and control of BP and lipids in patients with hypertension and additional risk factors. Am J Cardiovasc Drugs, 2007, 7(5): 381-389.
6. Liang K, Sheu WH, Lee W, et al. Coronary artery disease progression is associated with C-reactive protein and conventional risk factors but not soluble CD 40 ligand. Canadian J Cardiol, 2006, 22 (8): 691-696.
7. Haffner SM. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care, 2004, 27 (Suppl 1): S568-S571.
8. Wang BS, Yu HM, Chang LW, et al. Protective effects of pu-erh tea on LDL oxidation and nitric oxide generation in macrophage cells, LWT Food Sci Technol, 2008, 41(6): 1122-1132.
9. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J, 2001, 15(12): 2073-2084.
10. Brites F, Zago V, Verona J, et al. HDL capacity to inhibit LDL oxidation in well-trained triathletes. Life Sci, 2006, 78 (26): 3074-3081.
11. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prvent atherosclerosis and coronary heart disease. Pharmacol Ther, 2006, 111(3): 893-908.